Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome
NCT ID: NCT00350064
Last Updated: 2008-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
165 participants
INTERVENTIONAL
2004-04-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise Training
16 weeks of aerobic exercise training at two different intensities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Screening biochemical tests of liver, kidney, hematologic, metabolic (below) and thyroid function must be normal.
* The volunteer must be willing to:
1. visit the outpatient GCRC or clinic once monthly for 16 weeks of intervention,
2. participate in supervised exercise training (if assigned) and
3. enter the inpatient GCRC for 2-3 days of more intensive studies at baseline and after 16 weeks of intervention. The subject must provide voluntary and fully informed written consent.
Exclusion Criteria
* drug or alcohol abuse,
* psychosis,
* severe or untreated depression,
* dementia, polycythemia (hematocrit \> 55%),
* clinically symptomatic coronary artery,
* pulmonary or orthopedic disease (which would disallow exercise training),
* history of vascular or peripheral nerve trauma,
* lymph node dissection,
* anemia, uncontrolled hypertension (\> 160/105 untreated or \> 145/95 treated),
* allergic to octafluoropropane, or nitroglycerine,
* weight loss or gain of 2 kg or more within the preceding 10 days,
* investigational drug use within five biological half-lives,
* treatment with ACE inhibitors or ARBs, thiazolindiones,
* 1st or 2nd generation anti-psychotics insulin, or Viagra,
* unwillingness to provide written informed voluntary consent,
* pregnant, breast feeding or use hormonal birth control.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Research Resources (NCRR)
NIH
University of Virginia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Virginia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arthur Weltman, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia
Brian A Irving, PhD
Role: STUDY_DIRECTOR
University of Virginia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia General Clinical Research Center
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVAHIC11145
Identifier Type: -
Identifier Source: org_study_id